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The expression of most genes in the human 
genome can yield >1 transcript through the 
process of alternative splicing of pre-messenger 
RNA. Alternatively spliced transcripts significantly 
increase the complexity of human gene products 
because they either influence transcript 
degradation levels or encode functional protein 
variants that differ in specific domains.1 Even with 
cutting-edge transcriptomic approaches, it has 
been extremely challenging to understand or 
predict the complex splicing patterns observed in 
tissues or in diseases such as cancer; therefore, 
a better understanding of how cells are able to 
regulate alternative splicing is required.
Our group previously characterised the molecular 
mechanisms regulating RAC1b, an alternative splice 
variant that is overexpressed in colorectal tumours. 
RAC1b displays altered activation and downstream 
signalling properties and is required for colorectal 
cancer cell survival.2 The method used by tumour 
cells to enhance this alternative splicing event 
remains largely unknown.
Alternative splicing is regulated through the binding 
of splicing factors to gene-specific sequence 
elements and can be modified by changing either 
the expression levels of competing factors, or their 
activity and subcellular localisation, through protein 
phosphorylation.3 The study of RAC1b revealed that 
two antagonistic SR protein-family splicing factors, 
SRSF1 and SRSF3, bind to regulatory sequence 
elements in the alternative exon and determine 
the rate of exon inclusion. While the inhibitory 
factor SRSF3 was found to be regulated at the 
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transcriptional level, the antagonistic SRSF1 was 
regulated through protein phosphorylation.4 
Interestingly, recent data revealed that colon 
epithelial cells increase RAC1b expression in an 
inflammatory environment, indicating the role of 
cytokine signalling as an upstream event that is 
necessary for changes in alternative splicing.5 
Here, we explore how signalling pathways are 
involved in the deregulation of alternative RAC1b 
splicing in colorectal tumour cells.
Using HT29 cells that represent serrated colorectal 
tumours, with both the BRAF gene mutation 
Val600Glu in one allele and RAC1b overexpression, 
we depleted 20 candidate splicing-regulatory 
protein kinase genes by RNA interference. 
It was found that AKT2, AKT3, GSK3β, and 
SRPK1 are all required to sustain RAC1b levels. 
While knockdown of AKT2 and AKT3 affected 
only RAC1b protein levels, suggesting a post- 
splicing effect, the depletion of GSK3β or SRPK1 
decreased RAC1b alternative splicing, an effect 
mediated through changes in splicing factor 
SRSF1. In particular, the knockdown of SRPK1, 
or pharmacological inhibition of its catalytic 
activity, reduced phosphorylation and subsequent 
translocation of SRSF1 to the nucleus, limiting its 
availability to promote the inclusion of alternative 
exon 3b into the RAC1b pre-messenger RNA.6 
This regulatory pathway was also found to 
be controlled by GSK3β. Interestingly, GSK3β 
phosphorylation was identified as a target of the 
anti-inflammatory drug ibuprofen, which inhibits 
RAC1b overexpression. 
This work advances the current research on 
aberrant splicing events in cancer and demonstrates 
that oncogenic signal transduction pathways 
deregulate alternative splicing. Moreover, our 
results show that alternative splicing may be drug 
revertible and promote exploitation of the growing 
list of kinase inhibitors as a therapeutic resource 
to correct splicing in cancer cells. 
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Colorectal cancer survivors have an elevated risk 
of comorbid disease, particularly cardiovascular 
(CV) disease, due to both the age at diagnosis 
(around 60 years) and shared lifestyle risk factors; 
namely, being overweight/obese, physical inactivity, 
poor diet, and smoking.1,2 BMI is the strongest 
correlate of comorbid CV disease in cancer 
survivors.2 Comorbid chronic conditions can have 
